# Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia

> **NCT03024086** · PHASE3 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 124 (estimated)

## Conditions studied

- Functional Dyspepsia

## Interventions

- **DRUG:** DWJ1252
- **DRUG:** Gasmotin

## Key facts

- **NCT ID:** NCT03024086
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-12
- **Primary completion:** 2017-04-25
- **Final completion:** 2017-04-25
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2019-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03024086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03024086, "Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03024086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*